The chief executive of Novartis sent employees an email Thursday seeking to contain intensifying political and business fallout over the revelation that the drug maker paid $1.2 million to President Trump’s personal lawyer to gain access to the White House.

“Yesterday was not a good day for Novartis,” wrote Vasant Narasimhan, a physician and former McKinsey consultant, who joined the drug maker more than a decade ago and oversaw global drug development before being promoted to chief executive this past February.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • While not the best thing to happen to NVS, we should wait to see how things shake out with the new CEO on this. If involved then he should be accountable but this may all have been done without his knowledge but only time will tell. This is not the same organization I worked at years back, and something like this is not shocking, but it is much to soon to lump all executives into this right now

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy